



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Timothy A. Springer et al      Art Unit : 1644  
Serial No. : 09/945,265      Examiner : Maher M. Haddad, Ph.D.  
Filed : August 31, 2001  
Title : MODIFIED POLYPEPTIDES STABILIZED IN A DESIRED CONFORMATION  
AND METHODS FOR PRODUCING SAME

**MAIL STOP RCE**


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This filing is being made with the filing of a Request for Continued Examination. No fee is required.

Respectfully submitted,

  
\_\_\_\_\_  
Ramon K. Tabtiang  
Reg. No. 55,658

Date: 18 January 2005


Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21012467.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


18 January 2005  
\_\_\_\_\_  
Date of Deposit  
\_\_\_\_\_  
Signature  
\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>15775-029001</b>	Application No. <b>09/945,265</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Timothy A. Springer et al</b>	
		Filing Date <b>August 31, 2001</b>	Group Art Unit <b>1644</b>

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	CA	2001-0031260	18 Oct. 2001	Lee et al.			
	CB	5,284,931	8 Feb. 1994	Springer, et al.			
	CC	5,288,854	22 Feb. 1994	Diamond, et al.			
	CD	5,395,929	7 Mar. 1995	Corbi , et al.			
	CE	5,460,945	24 Oct. 1995	Springer, et al.			
	CF	5,475,091	12 Dec. 1995	Springer, et al.			
	CG	5,489,533	6 Feb. 1996	Springer, et al.			
	CH	5,512,660	30 Apr. 1996	Springer, et al.			
	CI	5,514,555	7 May 1996	Springer, et al.			
	CJ	5,565,550	15 Oct. 1996	Springer, et al.			
	CK	5,599,676	4 Feb. 1997	Vonderheide , et al.			
	CL	5,612,216	18 Mar. 1997	Springer, et al.			
	CM	5,622,700	22 Apr. 1997	Jardieu et al.			
	CN	5,629,162	13 May 1997	deFougerolles , et al.			
	CO	5,686,265	11 Nov. 1997	Corbi , et al.			
	CP	5,739,032	14 Apr. 1998	Springer et al.			
	CQ	5,747,035	5 May 1998	Presta et al.			
	CR	5,821,337	13 Oct. 1998	Carter et al.			
	CS	5,831,036	3 Nov. 1998	Springer et al.			
	CT	5,849,896	15 Dec. 1998	Springer et al.			
	CU	5,869,046	9 Feb. 1999	Presta et al.			
	CV	5,877,295	2 Mar. 1999	Diamond et al.			
	CW	5,891,841	6 Apr. 1999	deFougerolles et al.			
	CX	5,914,112	22 June 1999	Bednar et al.			
	CY	5,948,758	7 Sep. 1999	Springer et al.			
	CZ	6,030,947	29 Feb. 2000	Corbi et al.			
	DA	6,037,454	14 Mar. 2000	Jardieu et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15775-029001	Application No. 09/945,265
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Timothy A. Springer et al	
		Filing Date August 31, 2001	Group Art Unit 1644

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	DB	6,096,871	1 Aug. 2000	Presta et al.			
	DC	6,121,022	19 Sept. 2000	Presta et al.			
	DD	6,121,428	19 Sept. 2000	Blank et al.			
	DE	6,358,510	19 Mar. 2002	Springer et al.			
	DF	6,436,403	20 Aug. 2002	Springer et al.			
	DG	6,511,664	28 Jan. 2003	Springer et al.			
	DH	6,582,698	4 Mar. 2003	Mizutani et al.			
	DI	6,683,158	27 Jan. 2004	Springer et al.			
	DJ	6,777,191	17 Aug. 2004	Springer et al.			
	DK	6,797,270	28 Sep. 2004	Springer et al.			


**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	DL	EP 440 351	7 Aug. 91	EPO				
	DM	WO 94/04188	3 Mar. 1994	WIPO				
	DN							
	DO							
	DP							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	DQ	Oxvig et al., <i>Conformational changes in tertiary structure near the ligand binding site of an integrin I domain.</i> , PNAS, 96: 2215-2200 (1999)
	DR	Landis et al., <i>Involvement of the "I" Domain of the LFA-1 in Selective Binding to Ligands ICAM-1 and ICAM-3</i> , J. Cell. Biol., 126:529-537 (1994)
	DS	Landis et al., <i>A Novel LFA-1 Activation Epitope Maps to the I Domain</i> , J. Cell. Biol., 120:1519-1527 (1993)
	DT	Larson et al., <i>Primary Structure of the Leukocyte Function-associated Molecule 1<math>\alpha</math> Subunit: an Integrin with an Embedded Domain Defining a Protein Superfamily</i> , J. Cell Biol., 108:703-712 (1989)
	DU	Dransfield et al., <i>Interaction of Leukocyte Integrins with Ligand Is Necessary but Not Sufficient for Function</i> , J. Cell. Biol., 116:1527-1535 (1992)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

 Substitute Form PTO-1449 (Modified) <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15775-029001	Application No. 09/945,265
	Applicant Timothy A. Springer et al		
	Filing Date August 31, 2001	Group Art Unit 1644	

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	DV	Bullard et al., <i>A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice</i> , PNAS, 93: 2116-2121 (1996)
	DW	Huang et al., <i>A Binding Interface on the I Domain of Lymphocyte Function-associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion molecule 1 (ICAM-1)</i> , J. Biol. Chem, 270:19008-19016 (1995)
	DX	Dransfield et al, <i>Divalent Cation Regulation of the Function of the Leukocyte Integrin LFA-1</i> , J. Cell Biol., 116:219-226 (1992)
	DY	Champe et al., <i>Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CA11a</i> , J. Bio.; Chem., 270:3 1388-1394 (1995)
	DZ	Kooyk et al., <i>Activation of LFA-1 through the Ca<sup>2+</sup>-dependent Epitope Stimulates Lymphocyte Adhesion</i> , J. Cell Biol., 112:345-354 (1991)
	EA	Keizer et al., <i>A Monoclonal Antibody (NKI-L16) Directed against a Unique Epitope on the <math>\alpha</math>-chain of Human Leukocyte Function Associated Antigen 1</i> . . . , J. Immunol 140:1393 (1988)
	EB	Qu et al., <i>Crystal structure of the I-domain from the CD11a./CD18 (LFA-1, <math>\alpha</math><sub>L</sub><math>\beta</math>2) Integrin</i> , PNAS, 92:10277-10281 (1995)
	EC	..., "National PBM Drug Monograph Efalizumab," <a href="http://www.vapbm.org">www.vapbm.org</a> p. 1-25 (February 2004).
	ED	
	EE	
	EF	
	EG	
	EH	
	EI	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	